Kallikrein gene therapy: A new strategy for hypertensive diseases

Immunopharmacology

Volumn 36, Issue 2-3, 1997, Pages 229-236

  Chao, Julie ^a   Chao, Lee ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; Hypertension; Somatic gene delivery; Spontaneously hypertensive rats; Tissue kallikrein

Indexed keywords

BETA GALACTOSIDASE; KALLIKREIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS; ESSENTIAL HYPERTENSION; GENE THERAPY; HUMAN; HUMAN CELL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KALLIKREIN KININ SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ROUS SARCOMA ONCOVIRUS; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; AVIAN SARCOMA VIRUSES; BETA-GALACTOSIDASE; BLOOD PRESSURE; CYTOMEGALOVIRUS; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HUMANS; HYPERTENSION; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; KALLIKREIN-KININ SYSTEM; KALLIKREINS; LAC OPERON; METALLOTHIONEIN; PLASMIDS; PROMOTER REGIONS (GENETICS); RATS; RATS, INBRED SHR; TIME FACTORS; TISSUE KALLIKREINS;

EID: 0030749514     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00026-X     Document Type: Conference Paper

References (23)

1. Ader, J.L., Pollock, D.M., Butterfield, M.I., Arendshorst, W.J., 1985. Abnormalities in kallikrein excretion in spontaneously hypertensive rats. Am. J. Physiol. 248, F396-F403.
2. Bellini, C., Ferri, C., Piccoli, A., Corlomagno, A., Di Francesco, L., Bonavita, M.S., Santucci, A., Balsano, F., 1993. The influence of salt-sensitivity on the blood pressure response to exogenous kallikrein in essential hypertensive patients. Nephron 65, 28-35.
3. Berry, T.D., Hasstedt, S.J., Hunt, S.C., Wu, L.L., Smith, J.B., Ash, K.O., Kuida, H., Williams, R.R., 1989. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13, 3-8.
4. Chao, J., Jin, L., Chen, L.M., Chen, V.C., Chao, L., 1996a. Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hum. Gene Ther. 7, 901-911.
5. Chao, J., Yang, R., Jin, L., Lin, K.F., Chao, L., 1996b. Kallikrein gene therapy in newborn and adult hypertensive rats. Can. J. Physiol. Pharmacol., in press.
6. Favaro, S., Baggio, B., Antonello, A., Zen, A., Cannella, G., Todesco, S., Borsatti, A., 1975. Renal kallikrein content of spontaneously hypertensive rats. Clin. Sci. Mol. Med. 49, 69-71.
7. Geller, R.G., Margolius, H.S., Pisano, J.J., Keiser, H.R., 1975. Urinary kallikrein excretion in spontaneously hypertensive rats. Circ. Res. 36 (Suppl. 1) (6), 103-106.
8. Gyurko, R., Wielbo, D., Phillips, M.I., 1993. Antisense inhibition of ATI receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49, 167-174.
9. Linz, W., Wiemer, G., Gohlke, P., Unger, T., Scholkens, B.A., 1995. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev. 47, 25-49.
10. Margolius, H.S., Horwitz, D., Pisano, J.J., Keiser, H.R., 1974. Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ. Res. 35, 820-825.
11. Margolius, H.S., Geller, R., De Jong, W., Pisano, J.J., Sjoerdsma, A., 1972. Altered urinary kallikrein excretion in rats with hypertension. Circ. Res. 30, 358-362.
12. Margolius, H.S., Geller, R., de Jong, W., Pisano, J.J., Sjoerdsma, A., 1971. Altered urinary kallikrein excretion in human hypertension. Lancet 2, 1063-1065.
13. Ogawa, K., Ito, T., Ban, M., Mochizuki, M., Satake, T., 1985. Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin. Wochenschr. 63, 332-336.
14. Overlack, A., Stumpe, K.O., Kolloch, R., Ressel, C., Krueck, F., 1981. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 3 (3 Pt 2), 118-121.
15. Pravenec, M., Ken, V., Kunes, J., Scicli, G., Carretero, O.A., Simonet, L., Kurtz, T.W., 1991. Co-segregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17, 242-246.
16. Song, Q., Chao, J., Chao, L., 1996. Liver-targeted expression of human tissue kallikrein induces hypotension in transgenic mice. Clin. Exp. Hypertens. 18, 975-993.
17. Uehara, Y., Hirawa, N., Kawabata, Y., Suzuki, T., Ohshima, N., Oka, K., Ikeda, T., Unger, T., Rettig, R., 1990. Development of genetic hypertension. Is there a critical phase?. Hypertension 16, 615-616.
18. Wang, C., Chao, L., Chao, J., 1995. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J. Clin. Invest. 95, 1710-1716.
19. Wang, J., Xiong, W., Yang, Z., Davis, T., Dewey, M.J., Chao, J., Chao, L., 1994. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23, 236-243.
20. Wielbo, D., Sernia, C., Gyurko, R., Phillips, M.I., 1995. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25, 314-319.
21. Woodley-Miller, C., Chao, J., Chao, L., 1989. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J. Hypertens. 7, 865-871.
22. Xiong, W., Chao, J., Chao, L., 1995. Muscle delivery of human tissue kallikrein gene reduces blood pressure in spontaneously hypertensive rats. Hypertension 25 (2), 715-719.
23. Zinner, S.H., Margolius, H.S., Rosner, B., Kass, E.H., 1978. Stability of blood pressure rank and urinary kallikrein concentration in childhood: An eight year follow-up. Circulation 58, 908-915.